Overview
Studying the Effects of Sibutramine on Eating Behavior
Status:
Terminated
Terminated
Trial end date:
2010-10-01
2010-10-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
Obesity is a major public health concern, and the search for useful pharmacologic interventions is ongoing. This study aims to develop a comprehensive series of assessments to directly assess eating behavior, cognitive functioning, and psychological functioning under sibutramine and placebo conditions.Phase:
Phase 4Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
New York State Psychiatric InstituteCollaborator:
AstraZenecaTreatments:
SibutramineCriteria
Inclusion Criteria:- moderately obese
- stable weight for a minimum of 3 months
- systolic blood pressure less than or equal to 140 mm Hg
- diastolic blood pressure less than or equal to 90 mm Hg
- pulse less than or equal to 95 beats per minute
- English language proficiency
Exclusion Criteria:
- on medications known to affect appetite, weight, or metabolism
- current or past history of: binge eating disorder, anorexia nervosa or bulimia
nervosa, major depression
- current or past evidence of psychosis, bipolar illness
- current or past history of alcohol or drug abuse or dependence
- known history of learning disorder or developmental disability
- current or past attention deficit hyperactivity disorders
- low platelet count
- current diabetes mellitus
- uncontrolled asthma, or controlled only with oral steroids
- hypothyroidism not adequately treated
- pregnancy, planning to become pregnant, or lactation within the previous 6 months
- history of neurological disorder or injury
- history of moderate or severe head injury
- waist circumference greater than 188 cm
- indwelling metallic object, non-removable metal jewelery, medicinal patch or recent
metallic ink tattoo
- pacemaker
- metallic implants
- medication patches
- significant claustrophobia
- color blindness